Vol 53 No 12

"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.

"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.

The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.

The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.

The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.

The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.

Christof Vulsteke, MD, PhD, discusses results from the KEYNOTE-905 trial, evaluating perioperative EV/pembrolizumab in cisplatin-ineligible MIBC.

Avvio Medical plans to submit a de novo application for clearance of the device in early 2026.

Initial data on pasritamig showed that the agent was well tolerated and had encouraging preliminary antitumor activity in patients with mCRPC.

Stephen J. Freedland, MD, reported that with combination enzalutamide/leuprolide, the risk of death was 40.3% lower vs leuprolide alone.

Andrea Necchi, MD, reported a pCR rate of 38% (95% CI, 28%-49%) for cohort 1 vs 28% (95% Ci, 16%-44%) for cohort 2.